Home Cart Sign in  
Chemical Structure| 1339928-25-4 Chemical Structure| 1339928-25-4

Structure of Fimepinostat
CAS No.: 1339928-25-4

Chemical Structure| 1339928-25-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively.

Synonyms: CUDC-907

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fimepinostat

CAS No. :1339928-25-4
Formula : C23H24N8O4S
M.W : 508.55
SMILES Code : O=C(C1=CN=C(N(CC2=CC3=NC(C4=CC=C(OC)N=C4)=NC(N5CCOCC5)=C3S2)C)N=C1)NO
Synonyms :
CUDC-907
MDL No. :MFCD22420823
InChI Key :JOWXJLIFIIOYMS-UHFFFAOYSA-N
Pubchem ID :54575456

Safety of Fimepinostat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Fimepinostat

epigenetics
PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110β

    PI3Kβ, IC50:54 nM

  • p110α

    PI3Kα, IC50:19 nM

  • p110δ

    PI3Kδ, IC50:39 nM

  • HDAC10

    HDAC10, IC50:2.8 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03002623 Thyroid Neoplasms|Poorly Diffe... More >>rentiated and Undifferentiated Thyroid Cancer|Differentiated Thyroid Cancer Less << PHASE2 TERMINATED 2018-02-12 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT05971758 Cushing Disease PHASE2 NOT_YET_RECRUITING 2025-01-25 -
NCT02674750 Relapsed and/or Refractory Dif... More >>fuse Large B-cell Lymphoma Including With Myc Alterations Less << PHASE2 COMPLETED 2019-05-28 University of California San F... More >>rancisco-Fresno, Fresno, California, 93701, United States|University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|University of Chicago, Chicago, Illinois, 60647, United States|Norton Cancer Institute, Louisville, Kentucky, 40207, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|University of Rochester, Rochester, New York, 55905, United States|University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, Oklahoma, 73104, United States|Cancer Care Associates, Tulsa, Oklahoma, 74104, United States|Penn State Hershey Cancer Institute-Clinical Trials Office, Hershey, Pennsylvania, 17033, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|University of Tennessee Cancer Center, Knoxville, Tennessee, 37920, United States|Tennessee Oncology Sarah Cannon, Nashville, Tennessee, 37203, United States|Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital Durán i Reynals, Servicio de Oncología, Barcelona, 08908, Spain|Hospital Universitario Puerta de Hierro, Madrid, 28220, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain Less <<
NCT02909777 Lymphoma|Neuroblastoma|Brain T... More >>umor|Solid Tumor Less << PHASE1 ACTIVE_NOT_RECRUITING 2025-01-25 University of California, San ... More >>Francisco, Benioff Children's Hospital, San Francisco, California, 94158, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Texas Children's, Baylor College of Medicine, Houston, Texas, 77030, United States Less <<
NCT02307240 Triple-Negative Breast Cancer|... More >>High-grade Serous Ovarian Cancer|Solid Tumors|NUT Midline Carcinoma Less << PHASE1 COMPLETED 2019-05-31 UCSF School of Medicine, San F... More >>rancisco, California, 94143, United States|Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.83mL

1.97mL

0.98mL

19.66mL

3.93mL

1.97mL

References

 

Historical Records

Categories